Medicines for schizophrenia fall into two broad buckets: daily pills or long-acting injectables. But patients could eventually get a third option that combines the best of both worlds: a once-weekly drug that helps them stay adherent to treatment but without the major sticking point of an injection.

Normally, the FDA focuses its approval power on new drugs and devices, but in a very meta twist, the agency has issued a stern disapproval of a proposal issued in its own name earlier this year.

Precision BioSciences has reacquired the global rights to its allogeneic CAR-T programs. The deal with Servier gives Precision control of assets including a clinical-phase CD19 candidate that it sold off back in 2016 for $105 million.

Agiliti, one of the largest medical device management companies in the U.S., has set the terms for a $500 million IPO, potentially delivering a $2.6 billion valuation through its public debut next week.

It’s a common surgeon’s dream: What if you could shrink yourself down, place yourself inside the patient, and fix them from the inside? By combining virtual reality and miniaturized robotics, Vicarious Surgical, with its approach in its name, is looking to do just that.

Although the question of what causes obesity is hotly debated, one theory is gaining traction among researchers who study metabolic diseases: It could be the body’s reaction to inflammation. A team of researchers in Spain pursued that idea—and found evidence that preventing inflammation with drug used to treat heart disease could be an effective strategy.

Scientists use different models to study human disease when it would be too early or ethically problematic to run experiments in humans. Those models aim to mimic human biology as closely as possible to allow more accurate results.

Long gone are the days of needing to meet face-to-face with a clinician to get a prescription, view lab results or even complete physical therapy exercises. Now, those tasks can be completed remotely and all in the same place: Omada Health’s digital health platform.

Need to automatically compile data gathered by an insulin pen and send it to a healthcare provider? There’s a device-connected app for that.

For people with diabetes, measuring and taking insulin injections before large meals has always been a pain, both mentally and physically. CeQur aims to tackle both with its long-awaited wearable insulin delivery patch, now heading toward a broader commercial launch with $115 million in venture capital funding.